Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
- Status
- RECRUITING
- Phase
- PHASE1
Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
- Status
- TERMINATED
- Phase
- PHASE2
Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy
- Status
- RECRUITING
- Phase
- PHASE2
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Status
- RECRUITING
- Phase
- PHASE3
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
- Status
- RECRUITING
- Phase
- PHASE2
Phase I/IIa Dose Finding Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in First Line Therapy of Metastatic Melanoma (TRINITY)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
MAQ-001 in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
The Sagittarius Trial
- Status
- RECRUITING
- Phase
- PHASE3
A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma
- Status
- RECRUITING
- Phase
- PHASE1